Product Description
LC28-0126 is a reactive oxygen species scavenger being developed for the treatment of various conditions caused by oxidative stress, such as oral mucositis, graft-versus-host disease, and lethal reperfusion injury in acute myocardial infarction. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32980184/)
Mechanisms of Action: Free Radical Scavenger
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: LG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: ST Elevation Myocardial Infarction
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LG-CYCL004 | P2 |
Unknown status |
ST Elevation Myocardial Infarction |
2018-08-01 |
|
| LG-CYCL003 | P1 |
Completed |
Healthy Volunteers |
2017-11-15 |
28% |
| LG-CYCL002 | P2 |
Completed |
ST Elevation Myocardial Infarction |
2015-06-01 |
|
| LG-CYCL001 | P1 |
Completed |
Healthy Volunteers |
2013-09-01 |